|
1
|
Torre LA, Islami F, Siegel RL, Ward EM and
Jemal A: Global Cancer in Women: Burden and Trends. Cancer
Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee S, Kim WG, Kim E, Ryoo IJ, Lee HK, Kim
JN, Jung SH and Yoo ID: Synthesis and melanin biosynthesis
inhibitory activity of (+/-)-terrein produced by Penicillium sp.
20135. Bioorg Med Chem Lett. 15:471–473. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Malmstrøm J, Christophersen C, Barrero AF,
Oltra JE, Justicia J and Rosales A: Bioactive metabolites from a
marine-derived strain of the fungus Emericella variecolor. J Nat
Prod. 65:364–367. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Phattanawasin P, Pojchanakom K, Sotanaphun
U, Piyapolrungroj N and Zungsontiporn S: Weed growth inhibitors
from Aspergillus fischeri TISTR 3272. Nat Prod Res. 21:1286–1291.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim D-S, Lee H-K, Park S-H, Lee S, Ryoo
IJ, Kim WG, Yoo ID, Na JI, Kwon SB and Park KC: Terrein inhibits
keratinocyte proliferation via ERK inactivation and G2/M cell cycle
arrest. Exp Dermatol. 17:312–317. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang F, Mijiti M, Ding W, Song J, Yin Y,
Sun W and Li Z: (+)-Terrein inhibits human hepatoma Bel 7402
proliferation through cell cycle arrest. Oncol Rep. 33:1191–1200.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YF, Wang SY, Shen H, Yao XF, Zhang FL
and Lai D: The marine-derived fungal metabolite, terrein, inhibits
cell proliferation and induces cell cycle arrest in human ovarian
cancer cells. Int J Mol Med. 34:1591–1598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liao WY, Shen CN, Lin LH, Yang YL, Han HY,
Chen JW, Kuo SC, Wu SH and Liaw CC: Asperjinone, a nor-neolignan,
and terrein, a suppressor of ABCG2-expressing breast cancer cells,
from thermophilic Aspergillus terreus. J Nat Prod. 75:630–635.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Porameesanaporn Y,
Uthaisang-Tanechpongtamb W, Jarintanan F, Jongrungruangchok S and
Thanomsub Wongsatayanon B: Terrein induces apoptosis in HeLa human
cervical carcinoma cells through p53 and ERK regulation. Oncol Rep.
29:1600–1608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shibata A, Ibaragi S, Mandai H, Tsumura T,
Kishimoto K, Okui T, Hassan NM, Shimo T, Omori K, Hu GF, et al:
Synthetic terrein inhibits progression of head and neck cancer by
suppressing angiogenin production. Anticancer Res. 36:2161–2168.
2016.PubMed/NCBI
|
|
13
|
Cairns RA, Khokha R and Hill RP: Molecular
mechanisms of tumor invasion and metastasis: An integrated view.
Curr Mol Med. 3:659–671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liotta LA and Stetler-Stevenson WG: Tumor
invasion and metastasis: An imbalance of positive and negative
regulation. Cancer Res. 51 Suppl 18:5054s–5059s. 1991.PubMed/NCBI
|
|
15
|
Sahai E and Marshall CJ: RHO-GTPases and
cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ridley AJ: Rho GTPases and actin dynamics
in membrane protrusions and vesicle trafficking. Trends Cell Biol.
16:522–529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ridley AJ: Rho GTPase signalling in cell
migration. Curr Opin Cell Biol. 36:103–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ridley AJ: Rho family proteins:
Coordinating cell responses. Trends Cell Biol. 11:471–477. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vega FM and Ridley AJ: The RhoB small
GTPase in physiology and disease. Small GTPases. Nov 22–2016.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bravo-Cordero JJ, Moshfegh Y, Condeelis J
and Hodgson L: Live cell imaging of RhoGTPase biosensors in tumor
cells. Methods Mol Biol. 1046:359–370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhuge Y and Xu J: Rac1 mediates type I
collagen-dependent MMP-2 activation. Role in cell invasion across
collagen barrier. J Biol Chem. 276:16248–16256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gebäck T, Schulz MM, Koumoutsakos P and
Detmar M: TScratch: A novel and simple software tool for automated
analysis of monolayer wound healing assays. Biotechniques.
46:265–274. 2009.PubMed/NCBI
|
|
23
|
Asano T, Tada M, Cheng S, Takemoto N,
Kuramae T, Abe M, Takahashi O, Miyamoto M, Hamada J, Moriuchi T, et
al: Prognostic values of matrix metalloproteinase family expression
in human colorectal carcinoma. J Surg Res. 146:32–42. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wanichwatanadecha P, Sirisrimangkorn S,
Kaewprag J and Ponglikitmongkol M: Transactivation activity of
human papillomavirus type 16 E6*I on aldo-keto reductase genes
enhances chemoresistance in cervical cancer cells. J Gen Virol.
93:1081–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koujan SE, Gargarib BP, Pirouzpanah S and
Khalili M: Matrix metalloproteinases and breast cancer. Thrita.
4:e219592015.
|
|
27
|
Prudnikova TY, Rawat SJ and Chernoff J:
Molecular pathways: Targeting the kinase effectors of RHO-family
GTPases. Clin Cancer Res. 21:24–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cherigo L, Lopez D and Martinez-Luis S:
Marine natural products as breast cancer resistance protein
inhibitors. Mar Drugs. 13:2010–2029. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Demasi M, Felicio A, Pacheco A, Leite H,
Limaa C and Andrade L: Studies on terrein as a new class of
proteasome inhibitors. J Braz Chem Soc. 21:299–305. 2010.
View Article : Google Scholar
|
|
30
|
Adams J and Kauffman M: Development of the
proteasome inhibitor Velcade (Bortezomib). Cancer Invest.
22:304–311. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mandai H, Omori K, Yamamoto D, Tsumura T,
Murota K, Yamamoto S, Mitsudo K, Ibaragi S, Sasaki A, Maeda H, et
al: Synthetic (+)-terrein suppresses interleukin-6/soluble
interleukin-6 receptor induced-secretion of vascular endothelial
growth factor in human gingival fibroblasts. Bioorg Med Chem.
22:5338–5344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee YH, Lee SJ, Jung JE, Kim JS, Lee NH
and Yi HK: Terrein reduces age-related inflammation induced by
oxidative stress through Nrf2/ERK1/2/HO-1 signalling in aged HDF
cells. Cell Biochem Funct. 33:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cirit M, Grant KG and Haugh JM: Systemic
perturbation of the ERK signaling pathway by the proteasome
inhibitor, MG132. PLoS One. 7:e509752012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fritz G, Just I and Kaina B: Rho GTPases
are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chan AY, Coniglio SJ, Chuang YY,
Michaelson D, Knaus UG, Philips MR and Symons M: Roles of the Rac1
and Rac3 GTPases in human tumor cell invasion. Oncogene.
24:7821–7829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gadea G, Sanz-Moreno V, Self A, Godi A and
Marshall CJ: DOCK10-mediated Cdc42 activation is necessary for
amoeboid invasion of melanoma cells. Curr Biol. 18:1456–1465. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nassar N, Cancelas J, Zheng J, Williams DA
and Zheng Y: Structure-function based design of small molecule
inhibitors targeting Rho family GTPases. Curr Top Med Chem.
6:1109–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Akbar H, Cancelas J, Williams DA, Zheng J
and Zheng Y: Rational design and applications of a Rac
GTPase-specific small molecule inhibitor. Methods Enzymol.
406:554–565. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Montalvo-Ortiz BL, Castillo-Pichardo L,
Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA,
Vlaar CP and Dharmawardhane S: Characterization of EHop-016, novel
small molecule inhibitor of Rac GTPase. J Biol Chem.
287:13228–13238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nagase H, Visse R and Murphy G: Structure
and function of matrix metalloproteinases and TIMPs. Cardiovasc
Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brown GT and Murray GI: Current
mechanistic insights into the roles of matrix metalloproteinases in
tumour invasion and metastasis. J Pathol. 237:273–281. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mitropoulou TN, Tzanakakis GN, Kletsas D,
Kalofonos HP and Karamanos NK: Letrozole as a potent inhibitor of
cell proliferation and expression of metalloproteinases (MMP-2 and
MMP-9) by human epithelial breast cancer cells. Int J Cancer.
104:155–160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Farabegoli F, Govoni M, Spisni E and Papi
A: EGFR inhibition by (−)-epigallocatechin-3-gallate and IIF
treatments reduces breast cancer cell invasion. Biosci Rep.
37:BSR201701682017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lou C, Zhu Z, Zhao Y, Zhu R and Zhao H:
Arctigenin, a lignan from Arctium lappa L., inhibits metastasis of
human breast cancer cells through the downregulation of MMP-2/-9
and heparanase in MDA-MB-231 cells. Oncol Rep. 37:179–184. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bakar F, Kilic-Kurt Z, Caglayan MG and
Olgen S: The effects of 1,3,5-trisubstituted indole derivatives on
cell growth, apoptosis and MMP-2/9 mRNA expression of MCF-7 human
breast cancer cells. Anticancer Agents Med Chem. 17:762–767. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Matsumoto Y, Tanaka K, Harimaya K,
Nakatani F, Matsuda S and Iwamoto Y: Small GTP-binding protein,
Rho, both increased and decreased cellular motility, activation of
matrix metalloproteinase 2 and invasion of human osteosarcoma
cells. Jpn J Cancer Res. 92:429–438. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Aiuti A, Webb IJ, Bleul C, Springer T and
Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for
human CD34+ hematopoietic progenitor cells and provides
a new mechanism to explain the mobilization of CD34+
progenitors to peripheral blood. J Exp Med. 185:111–120. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bartolomé RA, Molina-Ortiz I, Samaniego R,
Sánchez-Mateos P, Bustelo XR and Teixidó J: Activation of Vav/Rho
GTPase signaling by CXCL12 controls membrane-type matrix
metalloproteinase-dependent melanoma cell invasion. Cancer Res.
66:248–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
